Uniphar Durbin Ireland Limited and TFF Pharmaceuticals, Inc. announced the opening of an Expanded Access Program (EAP) enabling patients access to TFF-VORI in the United States, Australia, United Kingdom, Canada and select countries in Europe.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.21 USD | +8.33% | +2.31% | -68.52% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-68.52% | 6.85M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- TFFP Stock
- News TFF Pharmaceuticals, Inc.
- Uniphar Durbin Ireland Limited and TFF Pharmaceuticals, Inc. Announce Opening of Expanded Access Program for Voriconazole Inhalation Powder for Treatment of Pulmonary Aspergillosis and Other Voriconazole Responsive Fungal Pulmonary Infections